1. 22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. Issue 3 (September 2015) Authors: Nghiem, P.; Bhatia, S.; Daud, A.; Friedlander, P.; Kluger, H.; Kohrt, H.; Kudchadkar, R.; Lipson, E.; Lundgren, L.; Margolin, K.; Reddy, S.; Shantha, E.; Sharfman, W.; Sharon, E.; Thompson, J.; Topalian, S.; Cheever, M. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S720 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. (December 2022) Authors: Hassel, J.C.; Sarnaik, A.; Chesney, J.; Medina, T.; Hamid, O.; Thomas, S.; Wermke, M.; Domingo-Musibay, E.; Kirkwood, J.M.; Larkin, J.; Weber, J.S.; Arance Fernandez, A.M.; Rodriguez, J.F.; Thomas, I.; Corrie, P.G.; Gontcharova, V.; Wu, X.; Shi, W.; Kluger, H. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Abstracts from the 4th ImmunoTherapy of Cancer Conference: Prague, Czech Republic. 20–22 March 2017. (20th March 2017) Authors: Ženka, J.; Caisová, V.; Uher, O.; Nedbalová, P.; Kvardová, K.; Masáková, K.; Krejčová, G.; Paďouková, L.; Jochmanová, I.; Wolf, K. I.; Chmelař, J.; Kopecký, J.; Loumagne, L.; Mestadier, J.; D'agostino, S.; Rohaut, A.; Ruffin, Y.; Croize, V.; Lemaître, O.; Sidhu, S. S. Journal: Journal for immunotherapy of cancer Issue: Volume 5(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗